Another study by Sang et al., which was a phase II clinical trial of co-administration of CD-19- and CD-20- targeted CAR-T cells in 21 adult patients with R/R DLBCL, showed the objective response rate at 3 months of 81% (17/21) and CRR of 52.4% (11/21). Here, CD19 is linked to diffuse large B-cell lymphoma.